Literature DB >> 33465100

Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome.

Beza Jobira1,2, Daniel N Frank2, Lori J Silveira1,3, Laura Pyle1,3, Megan M Kelsey1,4, Yesenia Garcia-Reyes1, Charles E Robertson2, Diana Ir2, Kristen J Nadeau1,4, Melanie Cree-Green1,4.   

Abstract

OBJECTIVE: Hepatic steatosis (HS) is common in adolescents with obesity and polycystic ovary syndrome (PCOS). Gut microbiota are altered in adults with obesity, HS, and PCOS, which may worsen metabolic outcomes, but similar data is lacking in youth.
METHODS: Thirty-four adolescents with PCOS and obesity underwent stool and fasting blood collection, oral glucose tolerance testing, and MRI for hepatic fat fraction (HFF). Fecal bacteria were profiled by high-throughput 16S rRNA gene sequencing.
RESULTS: 50% had HS (N = 17, age 16.2±1.5 years, BMI 38±7 kg/m2, HFF 9.8[6.5, 20.7]%) and 50% did not (N = 17, age 15.8±2.2 years, BMI 35±4 kg/m2, HFF 3.8[2.6, 4.4]%). The groups showed no difference in bacterial α-diversity (richness p = 0.202; evenness p = 0.087; and diversity p = 0.069) or global difference in microbiota (β-diversity). Those with HS had lower % relative abundance (%RA) of Bacteroidetes (p = 0.013), Bacteroidaceae (p = 0.009), Porphyromonadaceae (p = 0.011), and Ruminococcaceae (p = 0.008), and higher Firmicutes:Bacteroidetes (F:B) ratio (47.8% vs. 4.3%, p = 0.018) and Streptococcaceae (p = 0.034). Bacterial taxa including phyla F:B ratio, Bacteroidetes, and family Bacteroidaceae, Ruminococcaceae and Porphyromonadaceae correlated with metabolic markers.
CONCLUSIONS: Obese adolescents with PCOS and HS have differences in composition of gut microbiota, which correlate with metabolic markers, suggesting a modifying role of gut microbiota in HS and PCOS.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33465100      PMCID: PMC7815089          DOI: 10.1371/journal.pone.0245219

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  43 in total

1.  PKC{delta} is activated in a dietary model of steatohepatitis and regulates endoplasmic reticulum stress and cell death.

Authors:  Michael W Greene; Christine M Burrington; Mary S Ruhoff; Andrew K Johnson; Tepsiri Chongkrairatanakul; Atipon Kangwanpornsiri
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 2.  Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Authors:  G Vernon; A Baranova; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-30       Impact factor: 8.171

3.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

Authors:  Michael R Charlton; Justin M Burns; Rachel A Pedersen; Kymberly D Watt; Julie K Heimbach; Ross A Dierkhising
Journal:  Gastroenterology       Date:  2011-07-02       Impact factor: 22.682

Review 4.  Gut Microbiota of Nonalcoholic Fatty Liver Disease.

Authors:  Reham M Abdou; Lixin Zhu; Robert D Baker; Susan S Baker
Journal:  Dig Dis Sci       Date:  2016-02-22       Impact factor: 3.199

5.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

6.  Factorial validity and invariance of a self-report measure of physical activity among adolescent girls.

Authors:  Robert W Motl; Rod K Dishman; Marsha Dowda; Russell R Pate
Journal:  Res Q Exerc Sport       Date:  2004-09       Impact factor: 2.500

7.  Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?

Authors:  Amalia Gastaldelli
Journal:  Clin Sci (Lond)       Date:  2017-11-06       Impact factor: 6.124

8.  Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.

Authors:  D Macut; K Tziomalos; I Božić-Antić; J Bjekić-Macut; I Katsikis; E Papadakis; Z Andrić; D Panidis
Journal:  Hum Reprod       Date:  2016-04-12       Impact factor: 6.918

9.  Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study.

Authors:  Lisa Lindheim; Mina Bashir; Julia Münzker; Christian Trummer; Verena Zachhuber; Bettina Leber; Angela Horvath; Thomas R Pieber; Gregor Gorkiewicz; Vanessa Stadlbauer; Barbara Obermayer-Pietsch
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

10.  Association between Polycystic Ovary Syndrome and Gut Microbiota.

Authors:  Yanjie Guo; Yane Qi; Xuefei Yang; Lihui Zhao; Shu Wen; Yinhui Liu; Li Tang
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

View more
  3 in total

1.  Bifidobacterium Is Enriched in Gut Microbiome of Kashmiri Women with Polycystic Ovary Syndrome.

Authors:  Saqib Hassan; Marika A Kaakinen; Harmen Draisma; Liudmila Zudina; Mohd A Ganie; Aafia Rashid; Zhanna Balkhiyarova; George S Kiran; Paris Vogazianos; Christos Shammas; Joseph Selvin; Athos Antoniades; Ayse Demirkan; Inga Prokopenko
Journal:  Genes (Basel)       Date:  2022-02-18       Impact factor: 4.096

2.  Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease.

Authors:  Hu Li; Nan-Nan Liu; Jian-Rui Li; Biao Dong; Mei-Xi Wang; Jia-Li Tan; Xue-Kai Wang; Jing Jiang; Lei Lei; Hong-Ying Li; Han Sun; Jian-Dong Jiang; Zong-Gen Peng
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

3.  Combined Oral Contraceptive Treatment Does Not Alter the Gut Microbiome but Affects Amino Acid Metabolism in Sera of Obese Girls With Polycystic Ovary Syndrome.

Authors:  Beza Tayachew; Heidi Vanden Brink; Yesenia Garcia-Reyes; Haseeb Rahat; Angelo D'Alessandro; Daniel N Frank; Charles E Robertson; Lori Silveira; Megan Kelsey; Laura Pyle; Melanie Cree-Green
Journal:  Front Physiol       Date:  2022-06-21       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.